Drugs / VGN-R08b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06272149 | Mar 2023 → Jan 2025 overdue | Gaucher disease type II | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07414290 | May 2026 → Sep 2027 expected | Parkinson disease | Shanghai Vitalgen BioPharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07603050 | May 2026 → May 2028 expected | Gaucher disease type III | Shanghai Vitalgen BioPharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGN-R08b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414290 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9)” NCT06272149 ↗ |
| Route | Other | “being injected directly into intracerebroventricular” NCT06272149 ↗ |